InvestorsHub Logo
Followers 11
Posts 573
Boards Moderated 0
Alias Born 02/12/2016

Re: None

Wednesday, 09/27/2017 10:48:20 AM

Wednesday, September 27, 2017 10:48:20 AM

Post# of 461947
CTAD Boston - November 1-4, 2017

LBP33: Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease
Mohammad Afshar, MD, PhD1
, Frédéric Parmentier, PhD1
, Ene I Ette, PhD2
, Emmanuel O Fadiran, PhD3
, Christopher U Missling, PhD3
;
(1)Ariana Pharma, Paris, France, (2)Anoixis Corp., Natick, MA, (3)Anavex Life Sciences Corp., New
York, NY
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News